The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials
Conclusions: The meta-analysis confirms that PD-1/PD-L1 inhibitors exclusive pose an increased risk of immune-related liver dysfunction than chemotherapy. PD-1/PD-L1 blockade in NSCLC and UC increase the risk of immune-related liver dysfunction, but not in melanoma (MM) and head-neck squamous cell carcinoma (HNSCC).
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Databases & Libraries | Drugs & Pharmacology | Hepatocellular Carcinoma | HNSCC | Liver | Liver Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma | Statistics | Study | Urology & Nephrology